| Today’s Big NewsOct 16, 2023 |
| By Kevin Dunleavy Pfizer has slashed its 2023 revenue projection by $9 billion because of declining demand for COVID products. The company now expects sales to reach between $58 billion and $61 billion, down from a prior range of $67 billion to $70 billion. Pfizer chalked up most of the decline to a $7 billion decrease in its projection for sales of oral antiviral Paxlovid. The company has also cut its forecast for sales of COVID vaccine Comirnaty by $2 billion. |
|
|
|
By Annalee Armstrong Howard Fillit, M.D., remembers a time when doctors didn’t have a name for the condition that robbed elderly patients of their memory. He’s a geriatrician and neuroscientist, but also the co-founder and chief science officer for the Alzheimer’s Drug Discovery Foundation. |
By Conor Hale Previously, CMS had limited reimbursements for the imaging procedure, which is capable of highlighting the disease’s telltale clumps of beta amyloid proteins within the brain. |
By Max Bayer Aldyera came clean about the prospects of its dry eye disease med, revealing that the FDA could soon reject it due to review issues. The FDA had suggested that the company run an additional clinical trial to confirm efficacy. |
|
November 14-15, 2023 | Free Virtual Event The Fierce Diversity, Equity, and Inclusion Forum is back again this year and better than ever. We are collaborating with our Fierce Healthcare Editorial Team to expand the topics and audience for this exciting program across two days. Providing a wide range of strategies and best practices for pharma and biotech companies looking to improve their diversity efforts across all areas of their business. Save your seat now! 
|
|
By Angus Liu AbbVie already shared last month that its Skyrizi had trounced Johnson & Johnson’s rival biologic drug Stelara in Crohn’s disease. Now, detailed trial results show just how decisive Skyrizi’s win is. |
By Max Bayer Ultragenyx and Mereo BioPharma are out with a new slice of data from a phase 2/3 trial of its brittle bone disease treatment, showing it significantly reduced the rate of fractures. The data continue to add momentum to setrusumab as phase 3 recruitment continues. |
By Andrea Park Right on schedule, after securing FDA de novo clearance for its digital therapeutic designed to help manage Type 2 diabetes, Better Therapeutics is beginning the commercial launch of the app. |
By Zoey Becker Bristol Myers Squibb's Opdivo can now treat completely resected stage 2B or 2C melanoma, adding to its existing approvals in stages 3 and 4 tumors and setting up an expanded market battle with Merck & Co.'s star Keytruda. |
By Nick Paul Taylor Novo Nordisk is putting its soaring sales to work, agreeing to pay up to $1.3 billion for KBP Biosciences’ phase 3 challenger to Bayer’s chronic kidney disease drug Kerendia. |
By Conor Hale Working with the Global Fund to Fight AIDS, Tuberculosis and Malaria, the companies aim to boost the adoption of AI programs that can spot the signs of TB-related lung abnormalities. |
By Nick Paul Taylor Omeros has stopped a phase 3 trial of narsoplimab in kidney disease patients after an interim analysis found it was destined to fail, adding another plot line to its epic, ongoing attempt to get the candidate to market. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease. |
|
|---|
|
|
|
Thursday, November 9, 2023 | 2pm ET / 11am PT Join us for this webinar to explore the transformative power of decentralized clinical trials. Learn how automation is reshaping the landscape of clinical development, empowering life sciences professionals to streamline processes, reduce costs, and accelerate drug development timelines. Register now. 
|
|
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Edison Ballroom, New York City |
|
|
| |
|
